ConductScience.org, home

Comparison · NCT01515345-b2866fcc

Standard Therapy vs Individualized Therapy: Definite Stent Thrombosis

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Standard Therapy vs Individualized Therapy: Definite Stent Thrombosis. Trial comparisons, record NCT01515345-b2866fcc. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01515345-b2866fcc

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.001510.0002660.00848wilson
Risk in group 2000.0111wilson
Risk difference, group 1 minus group 20.00151-0.009640.00848newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treat, for one more participant with the outcome on Standard Therapy than on Individualized Therapy664from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Standard Therapystandard dual antiplatelet therapy after PCI for all patient populations (stable CVD and ACS)1664OG000
Group 2Individualized Therapydual antiplatelet therapy modified according to clopidogrel on-treatment platelet reactivity measured by Multiplate Analyzer0343OG001

Outcome

Type
PRIMARY
Title
Definite Stent Thrombosis
Description
The angiographic or pathological confirmation of stent thrombosis is called definite stent thrombosis
Time frame
30 days
Population

Source ClinicalTrials.gov

Trial

Title
Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry
NCT number
NCT01515345
Phases
PHASE3
Conditions
Platelet Inhibition, Coronary Stent Implantation
Interventions
prasugrel or ticagrelor, Clopidogrel
Lead sponsor
Kaiser Franz Josef Hospital
Results first posted
2013-05-01

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01515345-b2866fcc